The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer
Abstract
Purpose: To update the 2000 ASCO guidelines on the role of bisphosphonates in women with breast cancer and address the subject of bone health in these women. Results: For patients with plain radiographic evidence of bone destruction, intravenous pamidronate 90 mg delivered over 2 hours or zoledronic acid 4 mg over 15 minutes every 3 to 4 weeks is recommended. There is insufficient evidence supporting the efficacy of one bisphosphonate over the other. Starting bisphosphonates in women who demonstrate bone destruction through imaging but who have normal plain radiographs is considered reasonable treatment. Starting bisphosphonates in women with only an abnormal bone scan but without evidence of bone destruction is not recommended. The presence or absence of bone pain should not be a factor in initiating bisphosphonates. In patients with a serum creatinine less than 3.0 mg/dL (265 μmol/L), no change in dosage, infusion time, or interval is required. Infusion times less than 2 hours with pamidronate or less than 15 minutes with zoledronic acid should be avoided. Creatinine should be monitored before each dose of either agent in accordance with US Food and Drug Administration (FDA) labeling. Oncology professionals, especially medical oncologists, need to take an expanded role in the routine and regular assessment of the osteoporosis risk in women with breast cancer. The panel recommends an algorithm for patient management to maintain bone health. Conclusion: Bisphosphonates provide a supportive, albeit expensive and non–life-prolonging, benefit to many patients with bone metastases. Current research is focusing on bisphosphonates as adjuvant therapy. Although new data addressing when to stop therapy, alternative doses or schedules for administration, and how to best coordinate bisphosphonates with other palliative therapies are needed, they are not currently being investigated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Diagnosis of osteoporosis and assessment of fracture risk
Kanis, J. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08761-5 · Cited by 2,260
Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer
Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., & DeMets, D. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261302 · Cited by 1,129
Winer, E. P., Hudis, C., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R., Edge, S. B., Gralow, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.121 · Cited by 1,031
Self-citationHortobagyi, G. N., Theriault, R. L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J., Knight, R. D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612123352401 · Cited by 1,026
Self-citationPathogenesis of bone fragility in women and men
Seeman, E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08706-8 · Cited by 909
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M., Coleman, R. E., Reitsma, D. J., et al. (2001) · PubMed · Cited by 896
Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J.-M., Jaeger, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011807 · Cited by 877
Clinical Use of Bone Densitometry: Scientific Review
Cummings, S. R., Bates, D., & Black, D. M. (2002) · JAMA · doi:10.1001/jama.288.15.1889 · Cited by 817
Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.
Bines, J., Oleske, D. M., & Cobleigh, M. A. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.5.1718 · Cited by 816
Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Diel, I. J., Solomayer, E.-F., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D., Kaufmann, M., & Bastert, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390601 · Cited by 809
Black, D. M., Arden, N. K., Palermo, L., Pearson, J., Cummings, S. R., & for the Study of Osteoporotic Fractures Research Group (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.5.821 · Cited by 800
Powles, T. J., Hickish, T., Kanis, J. A., Tidy, A., & Ashley, S. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.78 · Cited by 646
Fisher, B., Dignam, J., Bryant, J., & Wolmark, N. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.9.684 · Cited by 635
Hortobagyi, G. N., Theriault, R. L., Lipton, A., Porter, L., Blayney, D., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J. J., Knight, R. D., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2038 · Cited by 631
Self-citationRisk of Menopause During the First Year After Breast Cancer Diagnosis
Goodwin, P. J., Ennis, M., Pritchard, K. I., Trudeau, M., & Hood, N. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2365 · Cited by 606
IX: Summary of Meta-Analyses of Therapies for Postmenopausal Osteoporosis
Cranney, A., Guyatt, G., Griffith, L., Wells, G., Tugwell, P., Rosen, C., The Osteoporosis Methodology Group, & The Osteoporosis Research Advisory Group (2002) · Endocrine Reviews · doi:10.1210/er.2001-9002 · Cited by 604
Berenson, J. R., Hillner, B. E., Kyle, R. A., Anderson, K., Lipton, A., Yee, G. C., & Biermann, J. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.037 · Cited by 542
Self-citationCollapsing Focal Segmental Glomerulosclerosis Following Treatment with High-Dose Pamidronate
MARKOWITZ, G. S., APPEL, G. B., FINE, P. L., FENVES, A. Z., LOON, N. R., JAGANNATH, S., KUHN, J. A., DRATCH, A. D., & D'AGATI, V. D. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1261164 · Cited by 466
Shapiro, C. L., Manola, J., & Leboff, M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3306 · Cited by 440
Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast Cancer
Powles, T., Paterson, S., Kanis, J. A., McCloskey, E., Ashley, S., Tidy, A., Rosenqvist, K., Smith, I., Ottestad, L., Legault, S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.080 · Cited by 377
Screening for Osteoporosis in Postmenopausal Women: Recommendations and Rationale
U.S. Preventive Services Task Force* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-6-200209170-00014 · Cited by 344
Saarto, T., Blomqvist, C., Virkkunen, P., & Elomaa, I. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.10 · Cited by 341
Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer
Goss, P. E., & Strasser, K. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.881 · Cited by 298
Delmas, P. D., Balena, R., Confravreux, E., Hardouin, C., Hardy, P., & Bremond, A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.955 · Cited by 278
Saarto, T., Blomqvist, C., Välimäki, M., Mäkelä, P., Sarna, S., & Elomaa, I. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1341 · Cited by 265
A high incidence of vertebral fracture in women with breast cancer
Kanis, J. A., McCloskey, E. V., Powles, T., Paterson, A. H. G., Ashley, S., & Spector, T. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690188 · Cited by 258
Winer, E. P., Hudis, C., Burstein, H. J., Chlebowski, R. T., Ingle, J. N., Edge, S. B., Mamounas, E. P., Gralow, J., Goldstein, L. J., Pritchard, K. I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.020 · Cited by 200
Self-citationCosta, L., Demers, L. M., Oliveira, A. G., Schaller, J. A., Costa, E. B., de Moura, M. C., & Lipton, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.850 · Cited by 193
Self-citationReginster, J., Deroisy, R., Dougados, M., Jupsin, I., Colette, J., & Roux, C. (2002) · Osteoporosis International · doi:10.1007/s001980200129 · Cited by 120
Nelson, D. A., Jacobsen, G., Barondess, D. A., & PARFITT, A. M. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650100515 · Cited by 109
Safety and Efficacy of Bisphosphonates Beyond 24 Months in Cancer Patients
Ali, S. M., Esteva, F. J., Hortobágyi, G. N., Harvey, H., Seaman, J. J., Knight, R., Costa, L., & Lipton, A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3434 · Cited by 91
Self-citationCoukell, A. J., & Markham, A. (1998) · Drugs & Aging · doi:10.2165/00002512-199812020-00007 · Cited by 82
Oral progestogen‐only contraception may protect against loss of bone mass in breast‐feeding women
Caird, L., Reid‐Thomas, V., Hannan, W. J., Gow, S., & Glasier, A. F. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02788.x · Cited by 73
Castel, L. D., Bajwa, K., Markle, J. P., Timbie, J. W., Zacker, C., & Schulman, K. A. (2001) · Supportive Care in Cancer · doi:10.1007/s005200100249 · Cited by 72
Effects of Raloxifene After Tamoxifen on Breast and Endometrial Tumor Growth in Athymic Mice
O'Regan, R. M., Gajdos, C., Dardes, R. C., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.274 · Cited by 64
Roux, C., Pelissier, C., Fechtenbaum, J., Loiseau-Pérès, S., & Benhamou, C. L. (2002) · Osteoporosis International · doi:10.1007/s001980200021 · Cited by 62
Saarto, T., Vehmanen, L., Elomaa, I., Välimäki, M., Mäkelä, P. M., & BLOMQVIST, C. P. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1729 · Cited by 50
Giles, F. J., Faderl, S., Thomas, D. A., Cortes, J. E., Garcia‐Manero, G., Douer, D., Levine, A. M., Koller, C. A., Jeha, S. S., O'Brien, S. M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.023 · Cited by 41
The role of disodium pamidronate in the management of bone pain due to malignancy
Groff, L., Zecca, E., Conno, F. D., Brunelli, C., Boffi, R., Panzeri, C., Cazzaniga, M. E., & Ripamonti, C. I. (2001) · Palliative Medicine · doi:10.1191/026921601678320287 · Cited by 22
Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease
(2000) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0142(20000501)88:9
Berenson (2001) · doi:10.1002/1097-0142(20010401)91:7<1191::aid-cncr1119>3.0.co;2-0
Cited by
Ruggiero, S. L., Dodson, T. B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., & O'Ryan, F. (2014) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2014.04.031 · Cited by 2,905
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
Coleman, R. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0931 · Cited by 2,488
Khosla, S., Burr, D., Cauley, J., Dempster, D. W., Ebeling, P. R., Felsenberg, D., Gagel, R. F., Gilsanz, V., Guise, T., Koka, S., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0707onj · Cited by 1,650
Self-citationStopeck, A. T., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,597
Self-citationRuggiero, S. L., Dodson, T. B., Assael, L. A., Landesberg, R., Marx, R. E., & Mehrotra, B. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.01.009 · Cited by 1,328
Metadata
- Authors
- Hillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J., Yee, G. C., Janjan, N. A., Cauley, J. A., Blumenstein, B. A., Albain, K. S., Lipton, A., & Brown, S.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-11-01
- Volume
- 21
- Issue
- 21
- Pages
- 4042-4057
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2107118598
- Cited by
- 970
- References
- 46
- FWCI
- 29.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.